Half- and mixed-sandwich metallacarboranes for potential applications in medicine

Author:

Gozzi Marta1ORCID,Schwarze Benedikt1ORCID,Hey-Hawkins Evamarie2ORCID

Affiliation:

1. Universität Leipzig, Institut für Anorganische Chemie , Johannisallee 29 , 04103 Leipzig , Germany

2. Universität Leipzig, Institut für Anorganische Chemie , Johannisallee 29 , 04103 Leipzig , Germany , Phone: +49-341-9736151, Fax: +49-341-9739319

Abstract

Abstract Today, medicinal chemistry is still clearly dominated by organic chemistry, and commercially available boron-based drugs are rare. In contrast to hydrocarbons, boranes prefer the formation of polyhedral clusters via delocalized 3c2e bonds, such as polyhedral dicarba-closo-dodecaborane(12) (closo-C2B10H12). These clusters have remarkable biological stability, and the three isomers, 1,2- (ortho), 1,7- (meta), and 1,12-dicarba-closo-dodecaborane(12) (para), have attracted much interest due to their unique structural features. Furthermore, anionic nido clusters ([7,8-C2B9H11]2−), derived from the neutral icosahedral closo cluster 1,2-dicarba-closo-dodecaborane(12) by deboronation followed by deprotonation are suitable ligands for transition metals and offer the possibility to form metallacarboranes, for example via coordination through the upper pentagonal face of the cluster. The isolobal analogy between the cyclopentadienyl(–1) ligand (Cp) and [C2B9H11]2− clusters (dicarbollide anion, Cb2−) is the motivation in using Cb2− as ligand for coordination to a metal center to design compounds for various applications. This review focuses on potential applications of half- and mixed-sandwich-type transition metal complexes in medicine.

Funder

Verband der Chemischen Industrie

Sächsisches Staatsministerium für Wissenschaft und Kunst

Publisher

Walter de Gruyter GmbH

Subject

General Chemical Engineering,General Chemistry

Reference102 articles.

1. B. Jones, S. Adams, G. T. Miller, M. I. Jesson, T. Watanabe, B. P. Wallner. Blood102, 1641 (2003).

2. Bortezomib: B. A. Teicher, G. Ara, R. Herbst, V. J. Palombella, J. Adams. Clin. Cancer Res.5, 2638 (1999).

3. Bortezomib: E. S. Lightcap, T. A. McCormack, C. S. Pien, V. Chau, J. Adams, P. J. Elliott. Clin. Chem.46, 673 (2000).

4. Bortezomib: T. Hideshima, P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams, K. C. Anderson. Cancer Res.61, 3071 (2001).

5. Bortezomib: J. Adams, M. Behnke, S. W. Chen, A. A. Cruickshank, L. R. Dick, L. Grenier, J. M. Klunder, Y. T. Ma, L. Plamondon, R. L. Stein. Bioorg. Med. Chem. Lett.8, 333 (2016).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3